SCHEMBL4347258

SCHEMBL4347258

CN(Cc1ccc(Nc2ccccc2Cl)nc1)CC(O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CNR2 P34972 3/20 0.43
JAK2 O60674 5/20 0.42
JAK1 P23458 5/20 0.42
TYK2 P29597 5/20 0.42
JAK3 P52333 5/20 0.42
CDK4 P11802 2/20 0.42
CDK2 P24941 2/20 0.42
CCNE1 P24864 1/20 0.42
AOC3 Q16853 1/20 0.37
S1PR2 O95136 1/20 0.37
S1PR3 Q99500 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
AURKA O14965 2/20 0.36
RAB9A P51151 1/20 0.36
KCNJ1 P48048 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346732 0.89 KDM4E (0.45) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4346362 0.88 KDM4E (0.47) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4340550 0.85 MEN1 (0.45) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4343262 0.83 MEN1 (0.57) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4348017 0.83 MEN1 (0.57) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4343366 0.82 KDM4E (0.48) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4662702 0.77 JAK2 (0.42) CNR2JAK2JAK1TYK2JAK3
SCHEMBL4346767 0.75 MEN1 (0.55) MEN1KMT2AKDM4ESMN1; SMN2CNR2
SCHEMBL4662703 0.73 JAK2 (0.40) CNR2JAK2JAK1TYK2JAK3
SCHEMBL5964322 0.72 CNR2 (0.68) MEN1KMT2AKDM4ESMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US claimed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP claimed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO claimed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, OPRL1 MEN1 4775/4885KMT2A 2988/4885KDM4E 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.